Precision Medicine in Oncology® | Specialty

Long-Term Outcomes With PD-1 Monotherapy in NSCLC

October 18th 2019

Role of I/O With Chemotherapy in Advanced Squamous NSCLC

October 18th 2019

CheckMate 817 Dual Immune-Checkpoint Inhibition in ECOG PS 2

October 18th 2019

CheckMate 227: Combining CTLA-4 and PD-L1 in NSCLC

October 18th 2019

Targeted Therapy for KRAS-Mutant NSCLC

October 18th 2019

LIBRETTO-001: RET-Fusion Positive Metastatic NSCLC

October 18th 2019

Strategies for Approaching Frontline Therapy in EGFR+ NSCLC

October 18th 2019

FLAURA Trial: Impact of OS Data in Advanced NSCLC

October 18th 2019

New Technology Eases Information Overload in Precision Medicine

October 10th 2019

R. Steven Paulson, MD, discusses how to adapt to the era of precision medicine, the latest with liquid biopsies, and a unique diagnostic tool with the potential to revolutionize oncology.

Liquid Biopsies Are Shaping Future of Molecular Testing

October 9th 2019

Sreeni Chittoor, MD, FACP, discusses the role of liquid biopsies in non–small cell lung cancer and the advantages of using this type of assay compared with tissue-based genotyping across cancer types. 

Studies Add to Evidence of Utility of Blood-Based Biomarkers in NSCLC

October 7th 2019

Evidence is increasing that blood-based biomarkers have predictive utility in advanced non–small cell lung cancer. Going further, blood-based next-generation sequencing appears to have clinical utility in selecting targeted treatment in this setting.

Oncology Experts Preview Exciting Precision Medicine Research

October 7th 2019

Faculty from Texas Oncology and Quest Med Fusion highlight exciting ongoing research efforts at their respective institutions.

Larotrectinib Elicits Clinically Meaningful PFS Improvement Through GMI in TRK Fusion+ Cancers

October 4th 2019

Larotrectinib demonstrated a clinically meaningful improvement in progression-free survival compared with time to progression on prior treatment in patients with TRK fusion–positive cancers using a measure known as the growth modulation index.

Technology Advances Aid Treatment Decisions for Community Oncologists

October 3rd 2019

Molecular testing has become an imperative step in the treatment decision-making process for oncologists, and new technologies and assays are emerging to further help identify tumor abnormalities and at the right time.

CFS&reg Experts: Novel Therapies and Onco-Genomics Add Heft to Precision Medicine

October 2nd 2019

Co-chairs William K. Oh, MD, Adam M. Brufsky, MD, PhD, and Benjamin P. Levy, MD, preview key topics that will be covered at the 37th Annual CFS®: Innovative Cancer Therapy for Tomorrow symposium.

Osimertinib OS Data Herald New Frontline Standard for EGFR-Mutant NSCLC

September 28th 2019

Frontline treatment with osimertinib improved median overall survival by 6.8 months compared with erlotinib or gefitinib for patients with metastatic, EGFR-mutant non–small cell lung cancer.

NGS Key to Guiding Treatment Decisions in ALK+ NSCLC

September 26th 2019

Miguel A. Villalona-Calero, MD, discusses the availability of ALK inhibitors for patients with ALK-positive non–small cell lung cancer and the importance of implementing sequencing panels to guide treatment.

Larotrectinib Approved in Europe for NTRK+ Tumors

September 23rd 2019

The European Commission has approved larotrectinib for the treatment of certain adult and pediatric patients with solid tumors who have an NTRK gene fusion without a known acquired resistance mutation.

Emerging Biomarkers for Targeted Agents Show Promise in NSCLC

September 17th 2019

Alex A. Adjei, MD, PhD, a professor of oncology and pharmacology at Mayo Clinic, discussed the history of five target genes: NTRK, RET, MET, BRAF, and HER2, as well as the exciting data coming out for the lung cancer subset.

Liquid Biopsy Matches Tissue for NSCLC Treatment Guidance

September 12th 2019

Patients with advanced non–small cell lung cancer and actionable mutations had similar progression-free survival whether treatment guidance came from tissue or circulating tumor (ct)DNA analysis using the Guardant360 assay, a matched retrospective comparison showed.